Tranexamic Acid and Plasminogen/Plasmin Glaring Paradox in COVID-19.
COVID-19
SARS-CoV-2
acute lung injury
acute respiratory syndrome
angiotensin converting enzyme 2
fibrinolytic system
tranexamic acid
Journal
Endocrine, metabolic & immune disorders drug targets
ISSN: 2212-3873
Titre abrégé: Endocr Metab Immune Disord Drug Targets
Pays: United Arab Emirates
ID NLM: 101269157
Informations de publication
Date de publication:
2023
2023
Historique:
received:
28
12
2021
revised:
27
03
2022
accepted:
30
03
2022
pubmed:
6
8
2022
medline:
10
3
2023
entrez:
5
8
2022
Statut:
ppublish
Résumé
Coronavirus disease 2019 (COVID-19) is caused by a severe acute respiratory syndrome, coronavirus type 2 (SARS-CoV-2), leading to acute tissue injury and an overstated immune response. In COVID-19, there are noteworthy changes in the fibrinolytic system with the development of coagulopathy. Therefore, modulation of the fibrinolytic system may affect the course of COVID-19. Tranexamic acid (TXA) is an anti-fibrinolytic drug that reduces the conversion of plasminogen to plasmin, which is necessary for SARS-CoV-2 infectivity. In addition, TXA has anti-inflammatory, anti-platelet, and anti-thrombotic effects, which may attenuate the COVID-19 severity. Thus, in this narrative review, we try to find the beneficial and harmful effects of TXA in COVID-19.
Identifiants
pubmed: 35927893
pii: EMIDDT-EPUB-125246
doi: 10.2174/1871530322666220801102402
doi:
Substances chimiques
Fibrinolysin
EC 3.4.21.7
Plasminogen
9001-91-6
Tranexamic Acid
6T84R30KC1
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
35-45Informations de copyright
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.